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Background: The ambulatory arterial stiffness index (AASI) can be used to predict cardiovascular morbidity and
mortality in hypertensive patients. However, data on AASI in Chinese patients with chronic kidney disease (CKD) is
not available.
Methods: This cross-sectional study enrolled 583 CKD patients. Univariate and multivariate analyses were used to
evaluate the relationship between AASI and renal function and parameters of cardiovascular injury.
Results: Patients with a higher AASI had a higher systolic blood pressure, a lower estimated glomerular filtration
rate (eGFR), a higher serum cystatin C, a higher left ventricular mass index (LVMI) and carotid intima-media thickness
(cIMT). Univariate analyses showed that AASI was positively correlated with serum cystatin C (r=0.296, P < 0.001),
serum creatinine (r=0.182, P < 0.001), and LVMI (r = 0.205, P < 0.001) and negatively correlated with the eGFR
(r = –0.200, P < 0.001). Multivariate analyses revealed that serum cystatin C, eGFR, serum creatinine and LVMI were
independently correlated with AASI.
Conclusions: These data suggest that AASI was closely correlated with renal function and parameters of
cardiovascular injury in Chinese CKD patients. Good quality, long-term, large longitudinal trials to validate the role
of AASI in clinical practice for Chinese CKD patients.
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The rising prevalence and associated morbidity of chronic
kidney disease (CKD) has resulted in a significant disease
burden and became a major public health problem for
many countries [1]. Cardiovascular disease (CVD) is the
leading cause of premature death in patients with CKD
[2], so research on vascular changes in CKD patients is
very important. Reduced arterial elasticity has been
observed in CKD patients [3]. Fibroelastic intimal thickening,
an increased extracellular matrix, enhanced collagen density,
and vascular calcification seem to contribute to “stiffer”
arteries [4]. It has been demonstrated that vascular
stiffness can predict adverse cardiovascular outcomes in
patients with primary hypertension [5].* Correspondence: lou.tq@163.com
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reproduction in any medium, provided the orIn 1914, MacWilliam and Melvin stated that a loss of
elasticity in the arterial system influences diastolic blood
pressure (DBP) and its relationship with systolic blood
pressure (SBP). According to this basic principle, Li et al.
proposed a novel, easy-to-obtain index of arterial stiffness:
the ambulatory arterial stiffness index (AASI). AASI is
defined as 1 minus the regression slope of DBP plotted
against SBP obtained from individual 24-h blood pressure
(BP) recordings. They also described the close correlation of
AASI with pulse wave velocity (PWV) as well as central and
peripheral augmentation indices [6]. Moreover, Dolan et al.
showed that AASI can provide prognostic information
because it was a predictor of stroke and cardiac death in a
cohort of 11,291 patients [7]. Kikuya et al. also observed that
the AASI predicted mortality due to CVD and stroke over
and beyond pulse pressure [8]. Muxfeldt et al. demonstrated
that AASI was a predictor of cardiovascular morbidity
and mortality in 547 patients with resistant hypertension [9].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AASI has good reproducibility, with repeatability coefficients
of ≤60% [10]. AASI has good correlation with target-organ
damage in patients with primary hypertension [11,12].
However, some have criticized the significance of AASI in
assessing arterial compliance, especially in pediatric
populations [13,14]; what is more, few studies have
focused on AASI in Chinese CKD patients. Investigating
the relationship between AASI and target organ damage in
Chinese CKD patients is very important when considering
different life style, genetic factors, environment and the
primary cause of CKD in the Chinese population. Hence,
we carried out an observational study to identify the
relationship between AASI and target organ damage
in CKD patients residing in China.
Methods
Design and population of the study
The study protocol was approved by the ethics committee
of 3rd Hospital of Sun Yat-sen University. All of the study
participants provided written informed consent to be
included in the study. Six hundred and fifty consecutive in
patients with CKD were included from May 2010 to July
2012. A cross-sectional study was carried out in our
division. The exclusion criteria were: treatment with
corticosteroids or hormones; acute changes in the
estimated glomerular filtration rate (eGFR) >30% in the
previous 3 months; pregnancy; history of abuse of drugs
or alcohol; night or shift-work employment; acquired
immunodeficiency syndrome; cardiovascular disorders
(unstable angina pectoris, heart failure, life-threatening
arrhythmia, atrial fibrillation and grade III–IV retinopathy);
intolerance to ambulatory blood pressure monitoring
(ABPM); inability to communicate and comply with all
of the study requirements; or maintenance dialysis.
We excluded 67 patients for abnormal ABPM or incomplete
measurement of baseline characteristics. Therefore,
583 patients were enrolled into the study. Forty-nine
subjects had diabetic nephropathy and 109 patients had
immunoglobulin (Ig) A nephropathy in this group.
Assessment
1. ABPM: Patients underwent 24-h ABPM using a
TM-2430 monitor (A&D, Tokyo, Japan). Cuff size
was chosen based on arm circumference. The cuff
was fixed to the non-dominant arm. Three BP readings
were obtained in the morning (07:00 to 10:00)
concomitant with sphygmomanometric measurements
to ensure that the average of the two sets of values
differed by ≤5 mmHg. BP was recorded every 15 min
from 07:00 to 22:00, and from every 30 min from
22:00 to 07:00. The values for daytime and nighttime
periods were derived from diaries recorded by thepatients during ABPM. Monitoring was done on a
working day. Patients had no access to ABP values.
Strenuous physical activity was discouraged in all
patients during the monitoring period, and their daily
activities were comparable.
BP series were eliminated from the analysis if: >30%
of the measurements were lacking; they had missing
data for >3-h spans; they were collected from subjects
who were experiencing an irregular rest–activity
schedule or a nighttime sleep span <6 h or >12 h
during monitoring. Raw data were examined by
scatter plots. The regression slope of DBP on SBP
was computed to obtain the AASI (1-slope). The
diagnosis of hypertension was based on accepted
criteria for ABPM [15]: ambulatory blood pressure
was considered to be “normal” if the mean awake BP
was <135/85 mmHg for SBP/DBP or if the mean
bedtime BP was <120/70 mmHg.
2. BP measurement in the physician’s office: BP was
measured during a visit to the physician’s office
(8 am to 11 am) [16]. Briefly, measurements were
made in a quiet environment using a mercury
sphygmomanometer with the patient in a sitting
position after 5 min of rest. BP was not measured if
the patient had engaged in recent physical activity,
used tobacco, ingested caffeine, or eaten within the
previous 30 min. Values of SBP and DBP values
(Korotkoff ’s phase I and phase V, respectively) in
each visit were used to obtain a minimum of two BP
measurements at intervals of ≥1 min. For each visit
(baseline and after the drug shift), the reported
values of office BP were the mean of values recorded
during the 2 days in which the ABP device was
installed and removed. For all patients,
sphygmomanometric measurements were
undertaken by the same physician, who was not
aware of the results of ABP recordings.
3. Cardiac assessment: Cardiac structure was assessed
by two investigators trained for this purpose before
starting the study. Left ventricular volumes, mass,
systolic function and diastolic function were
assessed using 2-dimensional echocardiography.
Left ventricular mass was calculated using the
Duvereux method [17]. The left ventricular mass
index (LVMI) was obtained by calculating left
ventricular mass to height2.7 [18]. Left ventricular
systolic function was assessed by left ventricular
ejection fraction, and diastolic function was assessed
by early mitral inflow filling velocity (E), peak mitral
filling velocity at atrial contraction (A), E/A
deceleration time of the mitral E wave and tissue
Doppler velocity of the mitral annulus [19].
Wang et al. BMC Nephrology 2013, 14:257 Page 3 of 9
http://www.biomedcentral.com/1471-2369/14/2574. Carotid ultrasonography: Carotid intima-media
thickness (cIMT) was assessed by two trained
investigators before study commencement. A
SonoSite MicroMaxx Ultrasound System paired
with a 5–10-MHz Multifrequency High-resolution
linear transducer (Bothell, WA, USA) with
Sono-Calc IMT software was used for taking
automatic measurements of cIMT. This was
achieved by averaging three measurements taken
on each carotid artery (anterior, lateral and
posterior directions) and measuring the distance
between the leading edge of the lumen–intima
interface and the leading edge of the collagenous
upper layer of the adventitia using high-resolution
B-mode ultrasonography. Measurements were
taken in areas free of obvious atherosclerotic
plaque around the level of the carotid bifurcation.
5. Renal assessment: Kidney damage was assessed by
measuring the serum concentrations of creatinine,
which is measured by the enzymatic method,
traceable to the isotope dilution mass spectrometry.
The estimated glomerular filtration rate (eGFR)
was calculated using a modified version of the
Modification of Diet in Renal Disease (MDRD)
equation based on data from Chinese CKD patients
as follows [20]:
eGFR ¼ 175 standardizedScr‐1:234  age−0:179  0:79 if femaleð Þ
6. Other data collection: We also collected urine
samples from 07:00 to 07:00 the next day to detect
the extent of 24-h proteinuria. These patients were
asked to void their bladders at 07:00 to ensure
valid results. Proteinuria was measured by
immunoturbidimetry. In addition, medical history,
including demographic and laboratory data
[serum cystatin C, cholesterol, triglycerides (TGs),
high-density lipo-protein-cholesterol (HDL-C),
low-density lipoprotein-cholesterol (LDL-C), fasting
glucose, homocysteine, calcium , phosphate, and
intact parathyroid hormone (iPTH)] as well as current
therapy were obtained at the initial study visit. The
experimental data were measured using a Hitachi
7180 biochemistry auto-analyzer (Tokyo, Japan).
Statistical analyses
Continuous variables were expressed as the mean ± standard
deviation (SD). Frequency distributions were used for
qualitative variables. Non-parametric variables are
expressed as median and interquartile range. The log
transformation for proteinuria was done in view of the
skewed distribution of these data, and Ln (proteinuria + 1)
was used because some patients had low levels of
proteinuria.One-way analysis (ANOVA) or non-parametric test was
used to analyze differences among the quartiles of AASI
distribution. Pearson’s correlation coefficient was employed
to estimate the relationship between quantitative vari-
ables, and the chi-squared test was used to associate
qualitative variables. We employed multivariate linear
regression models to study the association of indices
of renal function (levels of cystatin C, serum creatinine,
eGFR and proteinuria) and cardiovascular damage
(LVMI, E/A ratio, cIMT) with AASI values. All values are
two-tailed. p < 0.05 was considered significant. Data were
analyzed using SPSS ver18.0 (SPSS, Chicago, IL, USA).
Results
1 Clinical characteristics of patients
Of 583 CKD patients (mean age, 43 ± 16 years;
male/female ratio, 1.45) only 49 (8.4%) had diabetes
mellitus (DM) but 109 (18.7%) had IgA
nephropathy. The mean AASI was 0.54 ± 0.17.
Univariate analyses showed that AASI was positively
related with age (r = 0.263, P < 0.001). The AASI in
patients with IgA nephropathy was 0.47 ± 0.18,
which was lower than non-IgA nephropathy patients
(P < 0.05). The AASI in DM patients was 0.57 ± 0.11,
which was similar to that seen in non-DM patients.
The main clinical characteristics of the study
population across the quartiles of AASI distribution
are shown in Table 1. Patients with a higher AASI
were older, and had: higher SBP (in the clinic, over
24-h, at daytime and at bedtime); higher mean BP;
smaller variability in DBP (mean, at daytime and at
bedtime); lower eGFR; higher serum levels of
cystatin C; lower levels of hemoglobin; higher serum
levels of phosphate; iPTH and calcium × phosphate;
higher LVMI and cIMT and a higher prevalence of
carotid arterial plaques.2 AASI is closely correlated with clinical parameters
Univariate analyses showed that AASI was
positively correlated with: serum levels of phosphate
(r = 0.178, P < 0.001); iPTH (r = 0.179, P < 0.001) and
calcium × phosphate (r = 0.163, P < 0.001); serum
levels of uric acid (r = 0.107, P = 0.01), and negatively
correlated with levels of hemoglobin (r = –0.203,
P < 0.001) and HDL-C (r =–0.096, P = 0.025) (Table 2).
Univariate analyses showed that AASI was positively
correlated with SBP in the clinic (r = 0.168,
P < 0.001), over 24 h (r = 0.311, P < 0.001), while at
daytime (r = 0.322, P < 0.001) and bedtime (r = 0.196,
P < 0.001). It was also positively correlated with
mean BP (r = 0.226, P < 0.001) and heart rate
(r = 0.09, P = 0.017). AASI was negatively correlated
with the variability of DBP over 24 h (r = –0.188,
Table 1 Characteristics of the study population by quartiles of AASI distribution
Variables Quartile1 Quartile2 Quartile3 Quartile4
(<0.42) (0.42 ~ 0.53) (0.54 ~ 0.63) (>0.63)
(n = 145) (n = 146) (n = 146) (n = 146)
Age (years) 36 ± 14 43 ± 16* 44 ± 17*# 48 ± 17*#&
Male:female ratio 81: 59 87:59 87:60 90:60
Number of diabetic 6 11 15 17
ACEIs or ARBs (%) 50.4 55.2 58.1 63.3
CCB (%) 18.4 21.5 24.6 27.8
Proteinuria (g/24h) 1.2(0.4-4.1) 1.3(0.5-3.3) 1.4(0.5-3.9) 1.2(0.6-3.2)
Hemoglobin (g/L) 121 ± 29 114 ± 30 113 ± 30* 105 ± 31*#&
Albumin (g/L) 33 ± 9 35 ± 22 33 ± 9 35 ± 8
Globulin (g/L) 23 ± 5 24 ± 5 24 ± 6 25 ± 6
Serum creatinine (μmol/L) 235 ± 215 329 ± 216* 338 ± 261*# 445 ± 254*#&
Serum Cystatin C (mg/L) 1.9 ± 1.5 2.4 ± 1.8* 2.6 ± 2.0*# 3.5 ± 2.5*#&
eGFR-MDRD (ml/min/1.73m2) 81(22-115) 51(10-103)* 47(12-102)* 27(6-89)*#&
Cholesterol (mmol/L) 6.3 ± 3.1 6.2 ± 3.0 6.2 ± 3.5 5.5 ± 2.8
Triglyceride (mmol/L) 2.1 ± 1.5 2.2 ± 1.4 2.5 ± 2.4 2.0 ± 1.9
LDL-C (mmol/L) 4.1 ± 2.5 4.0 ± 2.0 3.9 ± 2.5 3.5 ± 2.1
HDL-C (mmol/L) 1.3 ± 0.5 1.2 ± 0.5 1.2 ± 0.5 1.2 ± 0.4
Glucose (mmol/L) 5.0 ± 1.8 5.1 ± 1.9 5.2 ± 1.8 5.3 ± 2.0
Calcium (mg/dL) 8.6 ± 0.8 8.7 ± 0.9 8.4 ± 1.0# 8.5 ± 0.9
Phosphate (mmol/L) 4.1 ± 1.1 4.5 ± 1.6* 4.5 ± 1.6* 4.9 ± 1.8*#&
Calcium × Phosphate (mg2/dl2) 35 ± 8 39 ± 13* 37 ± 10 41 ± 13*&
iPTH (pg/ml) 116 ± 98 139 ± 94 155 ± 130* 217 ± 167*#&
Urine acid (mmol/L) 433 ± 150 460 ± 156 466 ± 146 470 ± 157
homocysteine (μmol/L) 14.3 ± 8.6 18.2 ± 10.0* 16.8 ± 8.4* 16.2 ± 7.9*
LVEF (%) 63 ± 18 64 ± 16 66 ± 12 65 ± 14
LVMI (g/m2.7) 43 ± 15 49 ± 17* 56 ± 27* 54 ± 19*
E/A ratio 1.3 ± 0.4 1.1 ± 0.4* 1.2 ± 0.6 1.1 ± 0.4*
cIMI (mm) 0.61 ± 0.22 0.64 ± 0.21 0.68 ± 0.25 0.73 ± 0.35*#
Number of plaque 6 10 19* 20*
Clinic- SBP (mmHg) 135 ± 21 141 ± 23* 146 ± 24* 145 ± 26*
Clinic-DBP (mmHg) 84 ± 14 85 ± 15 87 ± 14 84 ± 14
average-SBP (mmHg) 126 ± 17 131 ± 20* 138 ± 20*# 142 ± 20*#
average-DBP (mmHg) 78 ± 11 79 ± 12 82 ± 12 81 ± 11
SBP-daytime (mmHg) 128 ± 17 134 ± 18* 138 ± 19*# 143 ± 19*#&
DBP-daytime (mmHg) 79 ± 11 81 ± 11 82 ± 12 82 ± 11
SBP-bedtime (mmHg) 110 ± 31 122 ± 39* 128 ± 31* 135 ± 28*#&
DBP-bedtime (mmHg) 67 ± 19 74 ± 16* 77 ± 20* 78 ± 15*#
Decline of SBP-bedtime 7.9 ± 7.0 6.3 ± 6.0 6.0 ± 14 4.5 ± 11.4
Decline of DBP-bedtime 10.6 ± 8.5* 7.2 ± 8.9* 6.6 ± 13.6* 3.6 ± 11.5*&
24h-MBP 93 ± 12 96 ± 14 100 ± 13 101 ± 113*#
Variability of SBP (%) 14 ± 8 15 ± 8 15 ± 11 13 ± 8
Variability of DBP (%) 24 ± 20 20 ± 9* 18 ± 10* 16 ± 6*#
Variability of SBP-daytime (%) 13 ± 5 14 ± 5 13 ± 4# 12 ± 4#
Wang et al. BMC Nephrology 2013, 14:257 Page 4 of 9
http://www.biomedcentral.com/1471-2369/14/257
Table 1 Characteristics of the study population by quartiles of AASI distribution (Continued)
Variability of DBP -daytime (%) 21 ± 7 19 ± 7* 17 ± 5*# 16 ± 5*#&
Variability of SBP-bedtime (%) 12 ± 6 12 ± 5 11 ± 6 10 ± 5*#
Variability of DBP -bedtime (%) 16 ± 7 16 ± 7 14 ± 6*# 13 ± 5*#
Pulse (beat/min) 75 ± 10 78 ± 10* 78 ± 11 78 ± 11
AASI (IU) 0.32 ± 0.08 0.48 ± 0.03* 0.59 ± 0.03*# 0.74 ± 0.08*#&
(AASI: ambulatory arterial stiffness index, ARB: angiotensin receptor blocker, ACEI: angiotensin-converting enzyme inhibitors, BMI: body mass index, CCB: calcium
channel blocker, eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; iPTH: intact parathyroid
hormone; LVEF: Left ventricular ejection fraction; LVMI: Left ventricular mass index; E: early mitral inflow filling velocity; A: peak mitral filling velocity at atrial contraction;
cIMI: Carotid intima-media thickness. Serum calcium is corrected by the following formula: [calcium] (mg/dL) =measured [calcium] + ( 4.0-[serum albumin (mg/dl)]) × 0.8;
SBP: systolic blood pressure; DBP: diastolic blood pressure; ABPM: ambulatory blood pressure monitoring. *indicated contro with Quartile1 P < 0.05, # indicated contro with
Quartile2 P < 0.05, &# indicated contro with Quartile3 P < 0.05).
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and bedtime (r = –0.162, P < 0.001). AASI was also
negatively correlated with SBP while at daytime
(r = –0.114, P = 0.006) and bedtime (r = –0.091,
P = 0.029) as well as the decline in bedtime SBP
(r = –0.124, P = 0.003) and DBP (r = –0.226,
P < 0.001) (Table 2).3 AASI is closely correlated with renal function
Univariate analyses revealed AASI was negatively
correlated with the eGFR (r = –0.200, P < 0.001) and
positively correlated with serum levels of cystatin C
(r = 0.296, P < 0.001) and serum creatinine(r = 0.182,
P < 0.001) Multiple linear regression analyses were
done to evaluate the relationship between eGFR,
serum levels of cystatin C and creatinine with AASI.
The eGFR was independently correlated with age
(β = -1.477), 24-h mean BP (β = -1.538), the decline
ratio of bedtime SBP (β =0.534) and the AASI
(β = –20.033). Serum levels of cystatin C were
independently correlated with age (β = 0.022), 24-h
mean BP (β =0.045), the decline in the ratio of
bedtime SBP (β = -0.038), and AASI (β = 1.795).
Serum creatinine were independently correlated
with sex (β = -91.657), 24-h mean BP (β = 9.259), the
decline in the ratio of bedtime SBP (β = -8.568) and
AASI (β = 262.347). A significant relationship
between AASI and proteinuria was not found when
univariate and multiple linear regression analyses
were undertaken (Tables 2 and 3).4 AASI is closely correlated with the LVMI
Univariate analyses showed that AASI was
positively correlated with the LVMI (r = 0.205,
P < 0.001) and cIMT (r = 0.156, P = 0.002), and
was negatively related to the E/A ratio (r = –0.114,
P = 0.018). However, we found that the LVMI
(but not the cIMT and E/A ratio) was
independently correlated with AASI (β = 1.712)
after multiple linear regression analyses were
carried out (Table 4).Discussion
In this clinical trial, we initially explored the relationship
between AASI and target-organ damage in CKD patients
in China. The mean AASI in our patients was 0.54, which
was higher than hypertensive patients in China [21].
Patients with a higher AASI were older and had: worse
renal function; more chronic CKD (anemia, higher serum
levels of phosphate and parathyroid hormone); higher
LVMI and cIMT; and higher BP. AASI was correlated
with renal function (eGFR and serum levels of cystatin C)
and LVMI according to univariate and multivariate ana-
lyses. This finding suggested that the AASI was a potential
index for the assessment of cardiovascular and renal
damage. Furthermore, AASI was significantly correlated
with variability in BP pressure, which suggested that AASI
might be a parameter for assessing BP variability.
AASI is derived from BP parameters and thus the
multiple reports on the correlation between AASI and
pulse pressure or systolic BP do not necessarily reflect
a true biological relationship. In a recent study using
a computer model of the arterial circulation, arterial
stiffness along with vascular resistance and heart rate
were identified as the main determinants of AASI [22].
Moreover, several studies have shown night BP reduction
to have considerable impact on AASI values [23]. Thus,
AASI cannot be considered as a marker of arterial stiffness
but rather as a composite index reflecting cardiovascular
properties, BP variability and diurnal cycle. Our results
showed AASI was correlated with target organ damage
and BP variability in CKD patients. This is the first report
on the relationship between AASI and target-organ
damage in a large cohort of Chinese CKD patients
based on cross-sectional data.
IgA nephropathy is the most common cause of
primary glomerulonephritis in “developing” countries
such as China [24], whereas diabetic nephropathy is
the main cause of end stage of renal disease in developed
countries [25]. Almost 20% patients in our study had IgA
nephropathy, and less than 10% patients suffered from
diabetic nephropathy, which is completely different
from that seen in western countries. Patients with IgA
Table 2 Baseline characteristics of clinical data and correlation coefficient with AASI
Variables N = 583 Correlation coefficient with AASI P value
Age (years) 43 ± 16 0.263 <0.001
Duration (months) 24 ± 17 0.075 0.074
BMI (kg/m2) 23 ± 4 −0.019 0.652
Ln (Proteinuria + 1) 1.0 ± 0.7 −0.007 0.867
Hemoglobin (g/L) 113 ± 30 −0.203 <0.001
Albumin (g/L) 34 ± 13 0.004 0.931
Globulin (g/L) 24 ± 6 0.098 0.02
Serum Cystatin C (mg/L) 2.6 ± 2.1 0.296 <0.001
Serum creatinine (μmol/L) 339 ± 222 0.182 <0.001
eGFR-MDRD (ml/min/1.73m2) 59 ± 48 −0.200 <0.001
Cholesterol (mmol/L) 6.1 ± 3.1 −0.089 0.039
Triglyceride (mmol/L) 2.2 ± 1.8 −0.028 0.517
LDL-C (mmol/L) 3.9 ± 2.4 −0.08 0.062
HDL-C (mmol/L) 1.2 ± 0.5 −0.096 0.025
Glucose (mmol/L) 5.2 ± 1.5 0.079 0.057
Calcium (mg/dL) 8.6 ± 0.8 −0.079 0.056
Phosphate (mmol/L) 4.5 ± 1.6 0.178 <0.001
Calcium × Phosphate (mg2/dl2) 36 ± 10 0.163 <0.001
iPTH (pg/ml) 157 ± 73 0.179 <0.001
Uric acid (mmol/L) 458 ± 163 0.107 0.010
homocysteine (μmol/L) 16.4 ± 8.8 0.067 0.143
LVEF (%) 63 ± 16 0.036 0.445
LVMI (g/m2.7) 51 ± 21 0.205 <0.001
E/A ratio 1.2 ± 0.5 −0.114 0.018
cIMI (mm) 0.7 ± 0.3 0.156 0.002
Clinic-SBP (mmHg) 142 ± 24 0.168 <0.001
Clinic-DBP (mmHg) 85 ± 14 −0.006 0.881
average-SBP (mmHg) 134 ± 20 0.311 <0.001
average-DBP (mmHg) 80 ± 12 0.128 0.002
SBP-daytime (mmHg) 136 ± 19 0.322 <0.001
DBP-daytime (mmHg) 81 ± 11 0.166 0.005
SBP-bedtime (mmHg) 124 ± 31 0.296 <0.001
DBP-bedtime (mmHg) 74 ± 18 0.216 <0.001
Decline of SBP-bedtime 6 ± 11 −0.124 0.003
Decline of DBP-bedtime 7 ± 11 −0.226 <0.001
24h-MBP 98 ± 13 0.226 <0.001
Variability of SBP (%) 14 ± 9 −0.039 0.352
Variability of DBP (%) 19 ± 13 −0.188 <0.001
Variability of SBP-daytime (%) 13 ± 4 −0.114 0.006
Variability of DBP-daytime (%) 18 ± 6 −0.283 <0.001
Variability of SBP-bedtime (%) 11 ± 6 −0.091 0.029
Variability of DBP-bedtime (%) 15 ± 6 −0.162 <0.001
Pulse (beat/min) 77 ± 10 0.09 0.017
AASI (IU) 0.54 ± 0.17 1.000 <0.001
(AASI: ambulatory arterial stiffness index, BMI: body mass index, eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density
lipoprotein cholesterol; iPTH: intact parathyroid hormone; LVEF: Left ventricular ejection fraction; LVMI: Left ventricular mass index; E: early mitral inflow filling velocity;
A: peak mitral filling velocity at atrial contraction; cIMI: Carotid intima-media thickness. Serum calcium is corrected by the following formula: [calcium] (mg/dL) =measured
[calcium] + ( 4.0-[serum albumin (mg/dl)]) × 0.8; SBP: systolic blood pressure; DBP: diastolic blood pressure; ABPM: ambulatory blood pressure monitoring).
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Table 3 Multiple linear regression analysis: relationship between renal parameters (eGFR, Serum Cystatin C, serum
creatinine and proteinuira) and AASI in CKD patients
Variables Not standardized b Confidence interval 95% P value
Dependent variable: eGFR by MDRD formula (Adjusted R2 = 0.322)
Age (year) −1.477 −1.685 ~ -1.263 <0.001
24h-MBP −1.538 −1.770 ~ -1.291 <0.001
decline ratio of bedtime SBP 0.534 0.225 ~ -0.834 0.001
AASI (IU) −20.033 −40.263 ~ -0.807 0.037
Dependent variable: Serum Cystatin C (Adjusted R2 = 0.304)
Age (year) 0.022 0.013 ~ 0.032 <0.001
24h-MBP 0.045 0.034 ~ 0.057 <0.001
Decline ratio of bedtime SBP −0.038 −0.054 ~ -0.021 <0.001
AASI (IU) 1.795 0.883 ~ 2.707 <0.001
Dependent variable: Serum creatinine (Adjusted R2 = 0.213)
Sex −91.657 −153.032 ~ -30.283 0.003
24h-MBP 9.259 6.940 ~ 11.579 <0.001
Decline ratio of bedtime SBP −8.568 −11.744 ~ -5.392 <0.001
AASI (IU) 262.347 78.405 ~ 446.289 0.005
Dependent variable: ln(proteinuria + 1) (Adjusted R2 = 0.034)
Age −0.008 −0.012 ~ -0.004 <0.001
24h-MBP 0.009 0.004 ~ 0.014 <0.001
Adjusted Variables: Age; Sex: (male = 1; female = 2).
Independent variable: ln (24Pro + 1), 24h-MBP, decline ratio of bedtime SBP, decline ratio of bedtime DBP, AASI (IU).
(AASI: ambulatory arterial stiffness index, eGFR: estimated glomerular filtration rate, MBP: mean blood pressure; SBP: systolic blood pressure).
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http://www.biomedcentral.com/1471-2369/14/257nephropathy are younger, and show less vascular complica-
tions, whereas patients with diabetic nephropathy are older
and have more micro and macro vascular complications.
All these factors mentioned in Chinese CKD patients might
lead to different roles of AASI in patients from western
countries. We found that AASI in IgA patients was lower
than non-IgA nephropathy patients, which was related to
being younger and having slight renal damage. HoweverTable 4 Multiple linear regression analysis: relationship betw
mass index, E/A ratio, Carotid intima-media thickness and Ca
Variables Not standardized β




decline ratio of bedtime SBP −0.274
AASI (IU) 1.712
Dependent variable: E/A ratio (Adjusted R2 = 0.283)
Age −0.014
24h-MBP −0.006
Dependent variable: Carotid intima-media thickness (Adjusted R2 = 0.305)
Age 0.009
Sex −0.070
Adjusted Variables: Age; Sex: (male = 1; female = 2).
Independent variable: eGFR-MDRD (ml/min/1.73m2), BMI, 24h-MBP, decline ratio of
(AASI: ambulatory arterial stiffness index, eGFR: estimated glomerular filtration rate,the number of subjects with diabetic nephropathy in the
present study was small, we need to study more diabetic
patients to confirm the role of AASI in patients with
diabetic nephropathy.
CVD is a leading cause of morbidity and mortality,
accounting for 30-40% of deaths in patients with renal
failure. Left ventricular hypertrophy, left ventricular
dilatation, systolic dysfunction and diastolic dysfunctioneen cardiovascular damage parameter (Left ventricular
rotid aterial plaque) and AASI in CKD patients
Confidence interval 95% P value
−0.183 ~ -0.103 <0.001
1.020 ~ 1.764 <0.001
0.012 ~ 0.313 0.034
−0.451 ~ -0.096 0.003
0.191 ~ 3.233 0.027
−0.016 ~ -0.011 <0.001
−0.009 ~ -0.003 <0.001
0.008 ~ 0.010 <0.001
−0.115 ~ -0.024 0.003
bedtime SBP, decline ratio of bedtime DBP, AASI (IU).
MBP: mean blood pressure; SBP: systolic blood pressure).
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http://www.biomedcentral.com/1471-2369/14/257are very common and independently associated with
mortality in CKD patients [26]. The cIMT is a marker for
the presence and severity of arteriosclerosis, and has been
associated with risk factors for all CVDs, all-cause mortality,
and cardiovascular mortality [27]. AASI is a well-known
predictor of cardiovascular mortality in hypertensive
patients [28]. However, there are few reports on the
relationship between AASI and cardiovascular damages.
We are the first to study this relationship in Chinese CKD
patients. We found that patients with higher AASI values
had a higher LVMI and cIMTas well as a higher prevalence
of carotid arterial plaques. Also, AASI was positively related
to the LVMI and cIMT. Our results indicated that AASI
was closely related to the traditional risk factors of CVD
such as LVMI and cIMT. AASI might be a potential marker
for the assessment of cardiovascular damage in CKD
patients and more clinical trials are needed to confirm
this finding.
Proteinuria is a strong, independent predictor of ESRD
in a mass-screening setting. Even a slight increase in
proteinuria is an independent risk factor for ESRD [29].
Proteinuria is strongly associated with arterial stiffness
and endothelial dysfunction [30], so proteinuria could
reflect arterial stiffness-associated increases. Data from
essential hypertension showed arterial stiffness correlated
with albumin excretion rate [31]. However, some authors
have reported that the 24-h albumin excretion rate did
not correlate with AASI [32], and baseline arterial stiffness
did not correlate with the incidence of microalbuminuria
[33]. A significant relationship between proteinuria
and the AASI was not found in our study even we used
different statistical methods, which might be related with
the complexcity of proteinuria in CKD patients. However,
we found AASI correlate with renal function (assessed by
eGFR, serum cystanic C and creatinine), which suggested
AASI might be a parameter for the assessment for the
progression of CKD, and more clinical trials are needed to
confirm this finding.
Our study had several strengths. We are the first
to report the close relationship between AASI and
cardiovascular/renal damage in CKD patients. Also,
the sample size was large. Finally, we reported the
relationship between AASI and renal cardiovascular
damage in Chinese CKD patients. However, we need
larger perspective studies to confirm the role of AASI in
Chinese CKD patients.
Conclusions
The present study provided evidence that AASI is associated
with renal function and cardiovascular risk factors in
Chinese CKD patients. AASI might be a potential index
for assessment in CKD patients. More clinical studies with
larger cohorts of patients are needed to confirm the role
of AASI in Chinese CKD patients.Abbreviations
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